Shilpa Medicare Ltd Q1 FY27 Earnings Analysis

- FY27 growth outlook is positive with scaling opportunities, especially in formulation and biologics. - European formulation business expects healthy growth, with multiple product launches planned in FY27. - Biologics segment projected to grow significantly in FY27 and FY28, driven by CDMO business, licensing income, and new product launches like Nivolumab and ADC. - API oncology product expansion underway, with steady growth expected rather than steep increase. - NorUDCA product shows steep QoQ growth post-launch; further scaling expected in FY27. - U.S. revenues expected to grow, focusing on super specialty products despite discontinuation of some generics. - EBITDA margins targeted to improve toward 35% over 1-2 years as operational leverage builds with growth. - Licensing income expected to remain robust with pipeline visibility. - Polymer business expected to grow steadily, though scaling to $20 million run rate may take time.

- EBITDA margins are currently at 29% with ambitions to reach 35% over the next 1-2 years, though immediate achievement is uncertain due to ongoing reinvestments for growth (Page 8, 18). - Robust growth is expected across biologics and formulations, with biologics revenue having doubled to INR150 crores in FY26 and expected to grow further driven by CDMO programs, licensing income, and biosimilar launches in FY27 and FY28 (Pages 9, 10, 18). - European formulation business, including products like Rotigotine and Nilotinib, is expected to see healthy growth with new product launches in FY27 and FY28, representing meaningful revenue drivers (Pages 7, 9, 16). - Licensing revenues are expected to sustain at similar or higher levels due to a strong pipeline of molecules and deals (Pages 8, 18). - ROCE improved to 17.4% in FY26 (excluding biologics investment) with expectations of further improvements as operating leverage kicks in (Pages 6, 18).

- FY26 capex was INR361 crores, funded primarily via internal accruals and deployed in key verticals: API, CDMO, and albumin facility. - For the current financial year, no significant increase in capex is expected compared to last year; capex will continue to sustain at similar levels. - Future investments focus on near-term and mid-term revenue-generating opportunities; no long-term, high gestation projects planned. - Investments made in high-growth biologics and NBE businesses amount to approximately INR700-800 crores (exact details to be confirmed from management). - Capex programs are expected to be primarily funded by internal accruals going forward. Overall, the company maintains a disciplined and focused capex approach targeting efficient scaling and growth without significant spikes in capital expenditure.

- The company’s interest outgo for FY26 has reduced year-on-year and is expected to stabilize at the current quarter run rate in the near future. - The company plans to fund its upcoming capex programs broadly via internal accruals. - There is no explicit mention of any new fundraising through debt or equity in the current or near future. - Net debt increased from INR550 crores in the previous year to INR613 crores in FY26, aligning with business growth. - Overall, the company appears focused on self-funding growth and capex through internal cash generation rather than external fundraising at this time.

The transcript does not explicitly provide precise figures or detailed commentary on the current or expected order book or pending orders for Shilpa Medicare Limited. However, some relevant insights can be inferred: - The company continues to demonstrate strong revenue growth with a healthy pipeline of molecules and products in formulation, biologics, and API segments. - Several products are under development or awaiting approvals, including biologics entering human global studies expected to commercialize by FY29. - Operations are supported by both in-house manufacturing and third-party CMOs; no capacity crunch is currently seen. - The company mentions a robust pipeline with milestone-based licensing income expectancies, though specific order values are not detailed. - No direct mention of order backlog or pending orders figures; queries referred to company officials (Monish) for detailed investment and order info. Hence, exact order book or pending order values are not disclosed in the document.